Tandem autotransplants of peripheral blood stem cells following sequential high-dose CHOEP chemotherapy for aggressive lymphoma.
- Author:
Yi LUO
1
;
He HUANG
;
Zhen CAI
;
Li LI
;
Wan-Zhuo XIE
;
Xiao-Jian MENG
;
Mao-Fang LIN
Author Information
1. Center of Bone Marrow Transplantation, The First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310003, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Child;
Combined Modality Therapy;
Cyclophosphamide;
therapeutic use;
Doxorubicin;
therapeutic use;
Etoposide;
therapeutic use;
Female;
Humans;
Lymphoma;
therapy;
Male;
Middle Aged;
Peripheral Blood Stem Cell Transplantation;
methods;
Prednisolone;
therapeutic use;
Retrospective Studies;
Survival Analysis;
Transplantation, Autologous;
Treatment Outcome;
Vincristine;
therapeutic use
- From:
Journal of Experimental Hematology
2005;13(4):628-630
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to evaluate the effecacy and safety of CHOEP mobilization regimen, and the effect and tolerance of sequential chemotherapy combined with tandem autotransplants of peripheral blood stem cells for aggressive lymphoma. The clinical data of 5 patients with recurrent, aggressive lymphoma treated with of sequential chemotherapy combined with tandem autotransplants were analyzed retrospectively. The patients included 1 HD and 4 NHL. Mobilization regimen was CHOEP combined with G-CSF 5 microg/(kg x d). The conditioning regimen for the tandem transplantation was high-dose CHOEP. The interval of the tandem autotransplantation was 9 (5 - 31) weeks. In tandem autotransplant, the cell number of MNC transfused was 3.05 (1.91 - 4.14) x 10(8)/kg and 3.55 (2.23 - 6.0) x 10(8)/kg; CD34(+) cells were 4.11 (2.59 - 4.94) x 10(6)/kg and 5.70 (2.77 - 10.6) x 10(6)/kg; CFU-GM was 2.96 (2.01 - 4.54) x 10(5)/kg and 2.44 (1.78 - 2.9) x 10(5)/kg respectively (P > 0.05). The results showed that all patients gained prompt and sustained hemotopoietic reconstitution. The interval of ANC >or= 0.5 x 10(9)/L was 10 (8 - 12) days and 10.5 (9 - 12) days; Pt >or= 2.0 x 10(9)/L was 11 (10 - 14) days and 12.5 (10 - 15) days respectively (P > 0.05). Four patients survived, three patients among them were alive in disease-free for median of 46 (9 - 88) months. The overall survival was 80%, and the disease-free survival was 60%. In conclusion, the method of sequential high-dose CHOEP chemotherapy combined with autotransplants of peripheral blood stem cells in tandem for aggressive lymphoma is probably safe and effective.
